Ruxolitinib in CMML: A Case Study of Innovative Trial Design in a Rare Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34531297.
- Also identified by DOI 10.1158/1078-0432.CCR-21-2578.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alternative statistical designs cannot fully mitigate the limitations of traditional clinical trials in rare cancers. Creative study designs that integrate early clinical data and correlative outcomes from concomitant translational and laboratory models to evaluate the efficacy of druggable targets can potentially expedite access to novel therapies for these patients.<i>See related article by Hunter et al., p. 6095</i>.
Medical subject headings
- Neoplasms
- Pyrimidines